Kirn David's most recent trade in 4D Molecular Therapeutics Inc was a trade of 267,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 267,500 | 267,500 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.49 per share. | 10 Jul 2024 | 12,923 | 1,059,153 | - | 22.5 | 290,598 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.42 per share. | 10 Jul 2024 | 11,653 | 1,070,806 | - | 14.4 | 168,036 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 11,653 | 565,417 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 1,270 | 148,730 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 10 Jul 2024 | 1,270 | 1,072,076 | - | 15.8 | 20,041 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.10 per share. | 24 Jun 2024 | 12,930 | 1,059,153 | - | 23.1 | 298,711 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.42 per share. | 24 Jun 2024 | 12,930 | 1,072,083 | - | 14.4 | 186,451 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 12,930 | 577,070 | - | - | Stock Option (Right To Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 27.13 per share. | 08 Feb 2024 | 92,001 | 1,059,153 | - | 27.1 | 2,495,822 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.41 per share. | 23 Jan 2024 | 5,696 | 1,151,154 | - | 18.4 | 104,851 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.31 per share. | 15 Dec 2023 | 40,732 | 1,185,087 | - | 20.3 | 827,202 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.27 per share. | 15 Dec 2023 | 28,632 | 1,230,521 | - | 17.3 | 494,432 | Common Stock |
| 4D Molecular Therapeutics Inc | Kirn David | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.56 per share. | 15 Dec 2023 | 28,104 | 1,156,983 | - | 19.6 | 549,804 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 15 Dec 2023 | 4,702 | 1,225,819 | - | 18.1 | 85,243 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.11 per share. | 15 Dec 2023 | 133 | 1,156,850 | - | 20.1 | 2,674 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 590,000 | 590,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2023 | 600,000 | 1,259,153 | - | 0 | Common Stock | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 02 May 2023 | 600,000 | 600,000 | - | 0 | Common Stock | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.93 per share. | 21 Feb 2023 | 17,090 | 1,876,509 | - | 20.9 | 357,718 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.22 per share. | 21 Feb 2023 | 16,449 | 1,859,153 | - | 20.2 | 332,665 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.49 per share. | 21 Feb 2023 | 907 | 1,875,602 | - | 21.5 | 19,491 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 222,000 | 222,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 19 Jan 2023 | 10,899 | 1,902,224 | - | 20.0 | 218,347 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.19 per share. | 19 Jan 2023 | 8,625 | 1,893,599 | - | 20.2 | 174,127 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 23.56 per share. | 15 Dec 2022 | 31,433 | 1,968,567 | - | 23.6 | 740,568 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 22.66 per share. | 15 Dec 2022 | 27,595 | 1,939,472 | - | 22.7 | 625,372 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 23.39 per share. | 15 Dec 2022 | 26,349 | 1,913,123 | - | 23.4 | 616,206 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 24.13 per share. | 15 Dec 2022 | 1,500 | 1,967,067 | - | 24.1 | 36,199 | Common Stock |
| 4D Molecular Therapeutics Inc | David Kirn | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | David Kirn | Director, See Remarks, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) |